Initial treatment of advanced ovarian carcinoma in combination with other chemotherapy agents. Secondary treatment for palliative treatment of patients with ovarian carcinoma recurrent after prior chemotherapy.
Small cell and non-small cell lung, head, neck, and testicular cancer.
Adults:IV 360 mg/m2 on day 1 every 4 wk if neutrophil count is at least 2,000/mm3 and platelet count is at least 100,000/mm3 .
Ovarian Carcinoma (Combination Therapy with Cyclophosphamide)
Adults:IV Carboplatin 300 mg/m2 plus cyclophosphamide 600 mg/m2 , both on day 1 every 4 wk for 6 cycles. Do not repeat intermittent courses of the combination until the neutrophil count is at least 2,000/mm3 and the platelet count is at least 100,000/mm3 .
Calvert Formula Dosing
Adults:IV Carboplatin may be dosed to achieve a target AUC based on the patient’s glomerular filtration rate (GFR) using the Calvert formula. The desired target AUC depends on the disease and the patient’s treatment status. The Calvert formula calculates the carboplatin dose in mg as follows: Total dose (mg) = target AUC (mg/mL•min) × (GFR [mL/min] + 25).
Dosage Adjustments Based on Lowest Posttreatment Blood Counts
Adults:IV If platelets above 100,000/mm3 and neutrophils above 2,000/mm3 , then give 125% of adjusted dose from prior course. If platelets are 50,000 to 100,000/mm3 and neutrophils are 500 to 2,000/mm3 , no dosage adjustment is necessary. If platelets below 50,000/mm3 and neutrophils below 500/mm3 , then give 75% of adjusted dose from prior course. Doses above 125% of the starting dose are not recommended.
Renal Function Impairment (Dosage Adjustment)
Adults:IV Baseline Ccr is 41 to 59 mL/min, the recommended dose on day 1 is 250 mg/m2 ; 16 to 40 mL/min is 200 mg/m2 ; below 15 mL/min, data too limited to permit a recommendation for treatment.